Creating lung cancer organoids from biopsy samples
Generation of Lung Tumor Organoids From Patients Undergoing Diagnostic Bronchoscopy
This study is trying to see if creating tiny lung cancer models from biopsy samples can help doctors better understand and treat the disease in patients undergoing bronchoscopy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Regina Elena Cancer Institute Academic / other |
| Locations | 1 site (Rome) |
| Trial ID | NCT06239584 on ClinicalTrials.gov |
What this trial studies
This study focuses on generating organoids from lung tumor tissue collected during diagnostic bronchoscopy procedures. It is a prospective pilot study that aims to collect additional tumor tissue to enhance the likelihood of successful organoid generation. Patients undergoing bronchoscopy for suspected lung cancer will be recruited, and the study will assess the feasibility of this approach in a clinical setting.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with suspected centrally located lung cancer who require diagnostic bronchoscopy.
Not a fit: Patients with medical contraindications to biopsy or those whose lung tumors are not accessible endoscopically may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to improved models for studying lung cancer and developing personalized treatment strategies.
How similar studies have performed: While the generation of organoids from tumor tissue is a growing field, this specific approach is novel and has not been extensively tested in lung cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with suspected diagnosis of centrally located and accessible lung cancer endoscopically; * patients for whom it is indicated to undergo in-depth diagnostic testing through bronchoscopy for the purpose of determining the histotype of the lung neoplasm, according to clinical practice standard; * aged over 18; * patients who express informed consent to the study. Exclusion Criteria: * medical contraindication to taking biopsy samples; * medical contraindication to carrying out endoscopic investigations; * patients with suspected lung cancer not accessible endoscopically; * patients with lung neoformation already subjected to diagnostic sampling; * contraindications to taking an additional quantity of tissue.
Where this trial is running
Rome
- "Regina Elena" National Cancer Institute — Rome, Italy (Recruiting)
Study contacts
- Principal investigator: Giovanni Blandino, Doctor — IRCCS "Regina Elena" National Cancer Institute
- Study coordinator: Giovanni Blandino, Doctor
- Email: giovanni.blandino@ifo.it
- Phone: 06-5266.2911
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.